Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $90.6667.

A number of brokerages recently issued reports on TARS. Oppenheimer began coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th.

Tarsus Pharmaceuticals Stock Down 3.3%

Tarsus Pharmaceuticals stock opened at $60.89 on Friday. The stock has a market cap of $2.62 billion, a PE ratio of -53.41 and a beta of 0.50. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The stock’s fifty day moving average is $62.08 and its two-hundred day moving average is $68.32. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. On average, sell-side analysts expect that Tarsus Pharmaceuticals will post -0.59 EPS for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the transaction, the director owned 106,786 shares in the company, valued at $6,633,546.32. This represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $60.95, for a total value of $877,436.20. Following the sale, the insider owned 56,801 shares in the company, valued at $3,462,020.95. This trade represents a 20.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 39,850 shares of company stock worth $2,452,821. Insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TARS. Rockefeller Capital Management L.P. lifted its stake in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after buying an additional 172 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares during the last quarter. State of Wisconsin Investment Board grew its position in shares of Tarsus Pharmaceuticals by 1.1% during the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after acquiring an additional 332 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 0.6% in the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares during the period. Finally, Valeo Financial Advisors LLC raised its position in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after purchasing an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.